UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 2, 2007
ADVENTRX Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
Delaware
(State or Other Jurisdiction of
Incorporation)
|
|
001-32157
(Commission File No.)
|
|
84-1318182
(IRS Employer Identification No.) |
6725 Mesa Ridge Road, Suite 100
San Diego, CA 92121
(Address of Principal Executive Offices and Zip Code)
N/A
(Former name or former address if changed since last report)
Registrant’s telephone number, including area code: (858) 552-0866
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 7.01. Regulation FD Disclosure.
Evan M. Levine, Chief Executive Officer of ADVENTRX Pharmaceuticals, Inc. (“ADVENTRX”), and other
executive officers will present the information reflected in the slides attached as Exhibit 99.1 to
this Current Report on Form 8-K (this “Report”) commencing November 2, 2007 at various investor
conferences and analyst meetings.
The information in this Report, including the slides attached hereto as Exhibit 99.1, is being
furnished pursuant to this Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of
that section, and it shall not be deemed incorporated by reference in any filing under the
Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof,
except as expressly set forth by specific reference in such filing to this Report.
By filing this Report and furnishing this information, ADVENTRX makes no admission as to the
materiality of any information in this Report. The information contained in the slides is summary
information that is intended to be considered in the context of ADVENTRX’s filings with the
Securities and Exchange Commission (the “SEC”) and other public announcements that ADVENTRX makes,
by press release or otherwise, from time to time. ADVENTRX does not intend and undertakes no duty
or obligation to publicly update or revise the information contained in this Report, although it
may do so from time to time as its management believes is appropriate. Any such updating or
revision may be made through the filing of other reports or documents with the SEC, through press
releases or through other public disclosure.
ADVENTRX cautions you that statements information included in the slides attached hereto as Exhibit
99.1 that are not a description of historical facts are forward-looking statements that involve
risks and assumptions that, if they materialize or do not prove to be accurate, could cause
ADVENTRX’s results to differ materially from historical results or those expressed or implied by
such forward-looking statements. These risks and uncertainties include, but are not limited to:
the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to
meet its anticipated or stated goals and milestones; the risk that preclinical results (including
bioequivalency results) are not indicative of the success of subsequent clinical trials (including
bioequivalence trials); difficulties or delays in developing, testing, manufacturing and marketing
and obtaining regulatory approval for ADVENTRX’s product candidates, including receiving necessary
regulatory approvals for clinical trials of ANX-514 and the potential for automatic injunctions and
other challenges by patent holders during the Section 505(b)(2) process; the potential for
regulatory authorities to require additional preclinical work or other clinical requirements to
support regulatory filings; the scope and validity of patent protection for ADVENTRX’s product
candidates; patent and non-patent exclusivity covering Navelbine® and Taxotere®; and other risks
and uncertainties more fully described in ADVENTRX’s press releases and periodic filings with the
Securities and Exchange Commission. ADVENTRX’s public filings with the Securities and Exchange
Commission are available at http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only
as of the date when made. ADVENTRX does not intend to update any forward-looking statement included
in the slides attached hereto as Exhibit 99.1 to reflect events or
circumstances arising after the date on which it was made. This caution is made under the safe
harbor provisions of Section 21E of the Securities Exchange Act of 1934.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The list of exhibits called for by this Item is incorporated by reference to the Index to
Exhibits filed with this report.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| |
|
|
|
|
|
|
|
|
| |
|
ADVENTRX PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
|
|
|
| Dated: November 2, 2007 |
|
By: |
|
/s/ Evan M. Levine |
|
|
| |
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Evan M. Levine |
|
|
|
|
|
|
Title:
|
|
Chief Executive Officer |
|
|